bluebird bio, Inc. (BLUE)
NASDAQ: BLUE · Real-Time Price · USD
0.298
-0.005 (-1.68%)
Nov 21, 2024, 2:04 PM EST - Market open
bluebird bio Revenue
bluebird bio had revenue of $10.61M in the quarter ending September 30, 2024, a decrease of -14.36%. This brings the company's revenue in the last twelve months to $53.12M, up 144.50% year-over-year. In the year 2023, bluebird bio had annual revenue of $29.50M with 720.04% growth.
Revenue (ttm)
$53.12M
Revenue Growth
+144.50%
P/S Ratio
1.00
Revenue / Employee
$141,653
Employees
375
Market Cap
57.92M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Procaps Group | 414.10M |
Xtant Medical Holdings | 113.86M |
Atara Biotherapeutics | 100.44M |
Exagen | 55.75M |
Champions Oncology | 51.66M |
Entera Bio | 99.00K |
BLUE News
- 1 day ago - My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys - Seeking Alpha
- 6 days ago - JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options - Benzinga
- 7 days ago - bluebird bio, Inc. (BLUE) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 days ago - bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance - Business Wire
- 14 days ago - bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call - Business Wire
- 16 days ago - bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition - Business Wire
- 6 weeks ago - Bluebird Bio (BLUE) Stock Dips Amid Market Volatility - GuruFocus
- 6 weeks ago - Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma - Seeking Alpha